Similar articles

• Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial.

  Messous S, Trabelsi I, Bel Haj Ali K, Abdelghani A, Ben Daya Y, Razgallah R, Grissa MH, Beltaief K, Mezgar Z, Belguith A, Bouida W, Boukef R, Boubaker H, Msolli MA, Sekma A, Nouira S. Messous S, et al. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099729. doi: 10.1177/17534666221099729. Ther Adv Respir Dis. 2022. Retraction in: Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251362671. doi: 10.1177/17534666251362671. PMID: 35657073 Free PMC article. Retracted. Clinical Trial.
• 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial.

  Mohamed Amine M, Selma M, Adel S, Khaoula BHA, Mohamed Hassene K, Imen T, Ahmed A, Nadia BB, Yosra BD, Rabie R, Mohamed Habib G, Kaouthar B, Mehdi M, Asma B, Wahid B, Riadh B, Hamdi B, Semir N; GREAT Network. Mohamed Amine M, et al. PLoS One. 2021 May 20;16(5):e0251716. doi: 10.1371/journal.pone.0251716. eCollection 2021. PLoS One. 2021. Retraction in: PLoS One. 2024 Jan 18;19(1):e0297557. doi: 10.1371/journal.pone.0297557. PMID: 34015041 Free PMC article. Retracted. Clinical Trial.
• Expression of concern: 'Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial'.

  [No authors listed] [No authors listed] Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231190750. doi: 10.1177/17534666231190750. Ther Adv Respir Dis. 2023. PMID: 37571965 Free PMC article. No abstract available.
• Chronic non-invasive ventilation for chronic obstructive pulmonary disease.

  Raveling T, Vonk J, Struik FM, Goldstein R, Kerstjens HA, Wijkstra PJ, Duiverman ML. Raveling T, et al. Cochrane Database Syst Rev. 2021 Aug 9;8(8):CD002878. doi: 10.1002/14651858.CD002878.pub3. Cochrane Database Syst Rev. 2021. PMID: 34368950 Free PMC article.
• Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

  Lenferink A, Brusse-Keizer M, van der Valk PD, Frith PA, Zwerink M, Monninkhof EM, van der Palen J, Effing TW. Lenferink A, et al. Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2. Cochrane Database Syst Rev. 2017. PMID: 28777450 Free PMC article.